PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna

Seeking AlphaMay 20 08:58

Capricor Therapeutics Initiated at Outperform by Oppenheimer

Capricor Therapeutics Initiated at Outperform by Oppenheimer

Dow JonesMay 17 04:47

Capricorn Therapeutics (CAPR.US) was first covered by Oppenheimer, which gave it an superior market rating and a target price of $14.00.

Capricorn Therapeutics (CAPR.US) was first covered by Oppenheimer, which gave it an superior market rating and a target price of $14.00.

Zhitong FinanceMay 17 04:40

Oppenheimer Initiates Coverage On Capricor Therapeutics With Outperform Rating, Announces Price Target of $14

Oppenheimer analyst Leland Gershell initiates coverage on Capricor Therapeutics with a Outperform rating and announces Price Target of $14.

Analyst UpgradesMay 17 04:37

Capricor Therapeutics: A Buy Rating Backed by Financial Stability and Promising DMD Treatment Developments

TipRanksMay 15 13:15

Expert Ratings For Capricor Therapeutics

During the last three months, 5 analysts shared their evaluations of Capricor Therapeutics (NASDAQ:CAPR), revealing diverse outlooks from bullish to bearish.The table below summarizes their recent rat

BenzingaMay 14 14:01